Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders

Joseph Hassett, George F. Gjerset, James W. Mosley, Mary Ann Fletcher, Elizabeth Donegan, John W. Parker, Richard B. Counts, Louis M. Aledort, Hang Lee, Malcolm C. Pike

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Patients with hemophilia A without human immunodeficiency virus type 1 (HIV-1) infection have lower CD4+ counts and CD4+/CD8+ ratios than controls. This is usually interpreted as a therapy-induced immunodeficiency. Our data re-examine the effect of therapy on peripheral blood mononuclear cell immunophenotypic subpopulations in all congenital clotting disorders. Since late 1985 we have prospectively observed HIV-1 uninfected persons with all types and severity of disorder. Controls were household members without clotting disorders or HIV-1 infection. Analyses of immunophenotype and treatment included a longitudinal random effects model. Compared with controls, age-adjusted CD4+ counts were significantly lower in treated patients (P < .0001) and in patients with all types of clotting disorders who were seldom or never treated (P = .0005). Significantly lower values among both treated and untreated clotting disorder subjects (P < .05) were likewise found for total lymphocytes, several other T-cell subsets, and the CD4+/CD8+ ratio. For most indexes, including the CD4+ count and CD4+/ CD8+ ratio, the type of clotting deficiency was not a significant variable. Comparing persons who had no or minimal therapy with those having the most showed increases in CD8+ (P = .0017) and CD20+CD21- counts (P = .0255), and a lower CD20+CD21+/CD20+ ratio (P = .0106) in the latter. Controls and persons with clotting disorders differ in CD4+ count. Among those with clotting factor disorders, there is no difference attributable to type of clotting disorder or factor therapy. Large amounts of treatment increased CD8+ and CD20+CD21- counts, but were not associated with a change in CD4+ count.

Original languageEnglish
Pages (from-to)1351-1357
Number of pages7
JournalBlood
Volume82
Issue number4
StatePublished - Aug 15 1993
Externally publishedYes

Fingerprint

Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Blood Coagulation Factors
Lymphocytes
Lymphocyte Subsets
Viruses
HIV-1
CD4 Lymphocyte Count
CD4-CD8 Ratio
Virus Diseases
T-cells
Therapeutics
Blood
Hemophilia A
T-Lymphocyte Subsets
Blood Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Hassett, J., Gjerset, G. F., Mosley, J. W., Fletcher, M. A., Donegan, E., Parker, J. W., ... Pike, M. C. (1993). Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. Blood, 82(4), 1351-1357.

Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. / Hassett, Joseph; Gjerset, George F.; Mosley, James W.; Fletcher, Mary Ann; Donegan, Elizabeth; Parker, John W.; Counts, Richard B.; Aledort, Louis M.; Lee, Hang; Pike, Malcolm C.

In: Blood, Vol. 82, No. 4, 15.08.1993, p. 1351-1357.

Research output: Contribution to journalArticle

Hassett, J, Gjerset, GF, Mosley, JW, Fletcher, MA, Donegan, E, Parker, JW, Counts, RB, Aledort, LM, Lee, H & Pike, MC 1993, 'Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders', Blood, vol. 82, no. 4, pp. 1351-1357.
Hassett J, Gjerset GF, Mosley JW, Fletcher MA, Donegan E, Parker JW et al. Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. Blood. 1993 Aug 15;82(4):1351-1357.
Hassett, Joseph ; Gjerset, George F. ; Mosley, James W. ; Fletcher, Mary Ann ; Donegan, Elizabeth ; Parker, John W. ; Counts, Richard B. ; Aledort, Louis M. ; Lee, Hang ; Pike, Malcolm C. / Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. In: Blood. 1993 ; Vol. 82, No. 4. pp. 1351-1357.
@article{a38bb20f161a43869d1da1b2d0e96f6d,
title = "Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders",
abstract = "Patients with hemophilia A without human immunodeficiency virus type 1 (HIV-1) infection have lower CD4+ counts and CD4+/CD8+ ratios than controls. This is usually interpreted as a therapy-induced immunodeficiency. Our data re-examine the effect of therapy on peripheral blood mononuclear cell immunophenotypic subpopulations in all congenital clotting disorders. Since late 1985 we have prospectively observed HIV-1 uninfected persons with all types and severity of disorder. Controls were household members without clotting disorders or HIV-1 infection. Analyses of immunophenotype and treatment included a longitudinal random effects model. Compared with controls, age-adjusted CD4+ counts were significantly lower in treated patients (P < .0001) and in patients with all types of clotting disorders who were seldom or never treated (P = .0005). Significantly lower values among both treated and untreated clotting disorder subjects (P < .05) were likewise found for total lymphocytes, several other T-cell subsets, and the CD4+/CD8+ ratio. For most indexes, including the CD4+ count and CD4+/ CD8+ ratio, the type of clotting deficiency was not a significant variable. Comparing persons who had no or minimal therapy with those having the most showed increases in CD8+ (P = .0017) and CD20+CD21- counts (P = .0255), and a lower CD20+CD21+/CD20+ ratio (P = .0106) in the latter. Controls and persons with clotting disorders differ in CD4+ count. Among those with clotting factor disorders, there is no difference attributable to type of clotting disorder or factor therapy. Large amounts of treatment increased CD8+ and CD20+CD21- counts, but were not associated with a change in CD4+ count.",
author = "Joseph Hassett and Gjerset, {George F.} and Mosley, {James W.} and Fletcher, {Mary Ann} and Elizabeth Donegan and Parker, {John W.} and Counts, {Richard B.} and Aledort, {Louis M.} and Hang Lee and Pike, {Malcolm C.}",
year = "1993",
month = "8",
day = "15",
language = "English",
volume = "82",
pages = "1351--1357",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders

AU - Hassett, Joseph

AU - Gjerset, George F.

AU - Mosley, James W.

AU - Fletcher, Mary Ann

AU - Donegan, Elizabeth

AU - Parker, John W.

AU - Counts, Richard B.

AU - Aledort, Louis M.

AU - Lee, Hang

AU - Pike, Malcolm C.

PY - 1993/8/15

Y1 - 1993/8/15

N2 - Patients with hemophilia A without human immunodeficiency virus type 1 (HIV-1) infection have lower CD4+ counts and CD4+/CD8+ ratios than controls. This is usually interpreted as a therapy-induced immunodeficiency. Our data re-examine the effect of therapy on peripheral blood mononuclear cell immunophenotypic subpopulations in all congenital clotting disorders. Since late 1985 we have prospectively observed HIV-1 uninfected persons with all types and severity of disorder. Controls were household members without clotting disorders or HIV-1 infection. Analyses of immunophenotype and treatment included a longitudinal random effects model. Compared with controls, age-adjusted CD4+ counts were significantly lower in treated patients (P < .0001) and in patients with all types of clotting disorders who were seldom or never treated (P = .0005). Significantly lower values among both treated and untreated clotting disorder subjects (P < .05) were likewise found for total lymphocytes, several other T-cell subsets, and the CD4+/CD8+ ratio. For most indexes, including the CD4+ count and CD4+/ CD8+ ratio, the type of clotting deficiency was not a significant variable. Comparing persons who had no or minimal therapy with those having the most showed increases in CD8+ (P = .0017) and CD20+CD21- counts (P = .0255), and a lower CD20+CD21+/CD20+ ratio (P = .0106) in the latter. Controls and persons with clotting disorders differ in CD4+ count. Among those with clotting factor disorders, there is no difference attributable to type of clotting disorder or factor therapy. Large amounts of treatment increased CD8+ and CD20+CD21- counts, but were not associated with a change in CD4+ count.

AB - Patients with hemophilia A without human immunodeficiency virus type 1 (HIV-1) infection have lower CD4+ counts and CD4+/CD8+ ratios than controls. This is usually interpreted as a therapy-induced immunodeficiency. Our data re-examine the effect of therapy on peripheral blood mononuclear cell immunophenotypic subpopulations in all congenital clotting disorders. Since late 1985 we have prospectively observed HIV-1 uninfected persons with all types and severity of disorder. Controls were household members without clotting disorders or HIV-1 infection. Analyses of immunophenotype and treatment included a longitudinal random effects model. Compared with controls, age-adjusted CD4+ counts were significantly lower in treated patients (P < .0001) and in patients with all types of clotting disorders who were seldom or never treated (P = .0005). Significantly lower values among both treated and untreated clotting disorder subjects (P < .05) were likewise found for total lymphocytes, several other T-cell subsets, and the CD4+/CD8+ ratio. For most indexes, including the CD4+ count and CD4+/ CD8+ ratio, the type of clotting deficiency was not a significant variable. Comparing persons who had no or minimal therapy with those having the most showed increases in CD8+ (P = .0017) and CD20+CD21- counts (P = .0255), and a lower CD20+CD21+/CD20+ ratio (P = .0106) in the latter. Controls and persons with clotting disorders differ in CD4+ count. Among those with clotting factor disorders, there is no difference attributable to type of clotting disorder or factor therapy. Large amounts of treatment increased CD8+ and CD20+CD21- counts, but were not associated with a change in CD4+ count.

UR - http://www.scopus.com/inward/record.url?scp=0027325655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027325655&partnerID=8YFLogxK

M3 - Article

C2 - 8353293

AN - SCOPUS:0027325655

VL - 82

SP - 1351

EP - 1357

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -